1,4-anthraquinone has been researched along with Leukemia L 1210 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Battina, SK; Hua, DH; Lou, K; Perchellet, EM; Perchellet, JP; Wang, Y; Zhao, H | 1 |
| Dalke, DM; Hua, DH; Huang, X; Magill, MJ; Perchellet, EM; Perchellet, JP | 1 |
2 other study(ies) available for 1,4-anthraquinone and Leukemia L 1210
| Article | Year |
|---|---|
Novel substituted 1,4-anthracenediones with antitumor activity directly induce permeability transition in isolated mitochondria.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Calcium; Cell Proliferation; Cyclosporine; Cytochromes c; HL-60 Cells; Humans; Leukemia L1210; Mice; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore | 2007 |
1,4-Anthraquinone: an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro.
Topics: Animals; Anthraquinones; Antibiotics, Antineoplastic; Biological Transport; Cell Survival; Daunorubicin; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; In Vitro Techniques; Leukemia L1210; Mitosis; Mitotic Index; Neoplasm Proteins; Nucleosides; RNA, Neoplasm; Tumor Cells, Cultured | 2000 |